Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

qPCR Microfluidics point-of-care platform for dengue diagnosis

Descrizione del progetto

Un test rapido per la diagnosi delle malattie trasmesse da vettori

Le malattie causate dai virus Dengue, Zika e Chikungunya vengono trasmesse all’uomo attraverso la zanzara Aedes femmina. Le analogie nei sintomi rendono impossibile una diagnosi differenziale, impedendo così un intervento medico appropriato e tempestivo. Per affrontare questo problema, gli scienziati del progetto DENVPOC, finanziato dall’UE, svilupperanno un test PCR multiplex rapido per discriminare i diversi virus. Il test PCR richiede solo un piccolo campione umano e può essere combinato con la pre-elaborazione automatica del campione e un sistema di microfluidica per ridurre tempi e costi. Ancora più importante, contribuirà al rapido screening delle donne in gravidanza e delle persone che vivono o viaggiano da o attraverso aree di epidemia.

Obiettivo

As a result of Global climate change and fast urbanization, global outbreaks of Dengue (DENV)/ Zika(ZIKV)/Chikungunya(CHIKV) virus have the potential to occur. The most common pathway of these infections in humans is through the female Aedes mosquito vector. DENV is an exanthematous febrile disease with varied clinical manifestations and progressions . Due to similarities in symptoms between DENV and ZIKV and CHIKV, it is difficult to make a differential diagnosis, impeding appropriate, timely medical intervention. Furthermore, cross-reactivity with ZIKV, which was recently related to microcephaly, is a serious issue. In 2016, in Brazil alone, there were 4180 microcephaly cases reported instead of 163 cases, more in line with yearly expected projections , , Thus, the sooner an accurate diagnostic which differentiates DENV from the other manifestations is critical; most especially at the early stages of the infection, to have a reliable diagnosis in pregnant women. In 2016, the OMS emergency committee declared that the outbreaks and the potentially resultant neurological disorders in Brazil were an important international state of emergency in public health, as a result of the associated secondary effects; these diseases became a Global concern. This project allows developing a highly and fast Multiplex qPCR POC platform by using FASTGENE technology with a minimal amount of patient serotype. It would reduce the time of analysis (30 to 90’ for a standard) and costs. Additionally, the sample preprocessing and thermalization will shorten real-time PCR amplification time and will be integrated within the microfluidic systems. This platform can result in a commercialized product whereupon a main market target would be pregnant women and people living or traveling through/from outbreak risk areas.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Coordinatore

BFORCURE
Contributo netto dell'UE
€ 196 707,84
Indirizzo
14 RUE DE LA BEAUNE
93100 Montreuil
Francia

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Ile-de-France Ile-de-France Seine-Saint-Denis
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 196 707,84